Crescent Biopharma, Inc.
CBIO
$14.47
-$0.23-1.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.95M | 3.60M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.03M | 14.23M | |||
| Operating Income | -21.03M | -14.23M | |||
| Income Before Tax | -21.79M | -15.15M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.79M | -15.15M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.79M | -15.15M | |||
| EBIT | -21.03M | -14.23M | |||
| EBITDA | -21.03M | -- | |||
| EPS Basic | -4.93 | -17.25 | |||
| Normalized Basic EPS | -3.53 | -11.75 | |||
| EPS Diluted | -4.93 | -17.25 | |||
| Normalized Diluted EPS | -3.53 | -11.75 | |||
| Average Basic Shares Outstanding | 3.86M | 805.80K | |||
| Average Diluted Shares Outstanding | 3.86M | 805.80K | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||